vs
Side-by-side financial comparison of BayCom Corp (BCML) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $25.9M, roughly 1.4× BayCom Corp). BayCom Corp runs the higher net margin — 26.5% vs -3.7%, a 30.2% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 9.4%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 2.9%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
BCML vs GYRE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $37.2M |
| Net Profit | $6.9M | $-1.4M |
| Gross Margin | — | 95.3% |
| Operating Margin | 36.6% | 0.3% |
| Net Margin | 26.5% | -3.7% |
| Revenue YoY | 9.4% | 33.4% |
| Net Profit YoY | 12.1% | -340.1% |
| EPS (diluted) | $0.63 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $37.2M | ||
| Q3 25 | $25.7M | $30.6M | ||
| Q2 25 | $24.7M | $26.8M | ||
| Q1 25 | $24.3M | $22.1M | ||
| Q4 24 | $23.7M | $27.9M | ||
| Q3 24 | $25.6M | $25.5M | ||
| Q2 24 | $23.8M | $25.2M | ||
| Q1 24 | $24.5M | $27.2M |
| Q4 25 | $6.9M | $-1.4M | ||
| Q3 25 | $5.0M | $5.9M | ||
| Q2 25 | $6.4M | $1.6M | ||
| Q1 25 | $5.7M | $3.7M | ||
| Q4 24 | $6.1M | $569.0K | ||
| Q3 24 | $6.0M | $2.9M | ||
| Q2 24 | $5.6M | $4.5M | ||
| Q1 24 | $5.9M | $9.9M |
| Q4 25 | — | 95.3% | ||
| Q3 25 | — | 94.7% | ||
| Q2 25 | — | 95.7% | ||
| Q1 25 | — | 95.9% | ||
| Q4 24 | — | 95.8% | ||
| Q3 24 | — | 96.2% | ||
| Q2 24 | — | 96.9% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | 36.6% | 0.3% | ||
| Q3 25 | 26.3% | 22.7% | ||
| Q2 25 | 35.3% | 8.1% | ||
| Q1 25 | 31.6% | 10.3% | ||
| Q4 24 | 34.2% | 2.4% | ||
| Q3 24 | 32.4% | 16.6% | ||
| Q2 24 | 31.9% | 12.7% | ||
| Q1 24 | 33.3% | 29.7% |
| Q4 25 | 26.5% | -3.7% | ||
| Q3 25 | 19.5% | 19.4% | ||
| Q2 25 | 25.8% | 5.9% | ||
| Q1 25 | 23.4% | 16.9% | ||
| Q4 24 | 25.9% | 2.0% | ||
| Q3 24 | 23.5% | 11.2% | ||
| Q2 24 | 23.6% | 18.0% | ||
| Q1 24 | 24.0% | 36.6% |
| Q4 25 | $0.63 | $-0.01 | ||
| Q3 25 | $0.46 | $0.03 | ||
| Q2 25 | $0.58 | $0.00 | ||
| Q1 25 | $0.51 | $0.00 | ||
| Q4 24 | $0.55 | $0.00 | ||
| Q3 24 | $0.54 | $0.01 | ||
| Q2 24 | $0.50 | $0.01 | ||
| Q1 24 | $0.51 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $52.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.6M | $106.0M |
| Total Assets | $2.6B | $166.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $52.4M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $54.4M | ||
| Q1 25 | — | $29.9M | ||
| Q4 24 | — | $26.7M | ||
| Q3 24 | — | $25.1M | ||
| Q2 24 | — | $25.1M | ||
| Q1 24 | — | $37.4M |
| Q4 25 | $338.6M | $106.0M | ||
| Q3 25 | $334.3M | $101.9M | ||
| Q2 25 | $330.6M | $92.0M | ||
| Q1 25 | $329.3M | $68.1M | ||
| Q4 24 | $324.4M | $63.3M | ||
| Q3 24 | $321.7M | $63.2M | ||
| Q2 24 | $315.3M | $60.4M | ||
| Q1 24 | $314.2M | $56.6M |
| Q4 25 | $2.6B | $166.1M | ||
| Q3 25 | $2.6B | $159.4M | ||
| Q2 25 | $2.6B | $152.6M | ||
| Q1 25 | $2.6B | $129.8M | ||
| Q4 24 | $2.7B | $125.4M | ||
| Q3 24 | $2.6B | $125.2M | ||
| Q2 24 | $2.6B | $120.9M | ||
| Q1 24 | $2.6B | $122.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-5.6M |
| Free Cash FlowOCF − Capex | $30.1M | $-5.8M |
| FCF MarginFCF / Revenue | 116.2% | -15.5% |
| Capex IntensityCapex / Revenue | 6.7% | 0.4% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | $-180.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $-5.6M | ||
| Q3 25 | $7.3M | $4.7M | ||
| Q2 25 | $6.4M | $2.1M | ||
| Q1 25 | $9.3M | $-129.0K | ||
| Q4 24 | $30.4M | $-2.8M | ||
| Q3 24 | $9.6M | $1.7M | ||
| Q2 24 | $7.7M | $-5.5M | ||
| Q1 24 | $5.1M | $2.9M |
| Q4 25 | $30.1M | $-5.8M | ||
| Q3 25 | $6.2M | $4.0M | ||
| Q2 25 | $5.6M | $1.8M | ||
| Q1 25 | $9.1M | $-251.0K | ||
| Q4 24 | $28.7M | $-2.8M | ||
| Q3 24 | $9.4M | $1.0M | ||
| Q2 24 | $7.4M | $-6.9M | ||
| Q1 24 | $3.9M | $2.7M |
| Q4 25 | 116.2% | -15.5% | ||
| Q3 25 | 24.3% | 13.1% | ||
| Q2 25 | 22.8% | 6.8% | ||
| Q1 25 | 37.6% | -1.1% | ||
| Q4 24 | 121.1% | -10.1% | ||
| Q3 24 | 36.6% | 4.1% | ||
| Q2 24 | 31.2% | -27.5% | ||
| Q1 24 | 16.1% | 9.8% |
| Q4 25 | 6.7% | 0.4% | ||
| Q3 25 | 4.3% | 2.2% | ||
| Q2 25 | 3.0% | 1.0% | ||
| Q1 25 | 0.6% | 0.6% | ||
| Q4 24 | 7.2% | 0.2% | ||
| Q3 24 | 1.0% | 2.7% | ||
| Q2 24 | 1.0% | 5.8% | ||
| Q1 24 | 4.7% | 0.9% |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | 0.79× | ||
| Q2 25 | 1.00× | 1.32× | ||
| Q1 25 | 1.63× | -0.03× | ||
| Q4 24 | 4.96× | -4.85× | ||
| Q3 24 | 1.60× | 0.60× | ||
| Q2 24 | 1.37× | -1.21× | ||
| Q1 24 | 0.86× | 0.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
